How to Get Evenity (Romosozumab) in Michigan

What Evenity (Romosozumab) Does and Why Access Matters

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by bone cells that blocks new bone formation. By suppressing sclerostin, the drug simultaneously builds new bone and slows bone breakdown. This dual mechanism makes it unique among osteoporosis treatments.

A Bone-Building Drug, Not Just an Anti-Resorptive

Most osteoporosis medications (bisphosphonates, denosumab) slow bone loss. Romosozumab actively increases bone mineral density. In the ARCH trial (N=4,093), romosozumab followed by alendronate reduced new vertebral fractures by 48% compared to alendronate alone at 24 months [1]. Lumbar spine BMD increased by 13.7% over the first 12 months of romosozumab treatment. That rate of gain is unmatched by any oral bisphosphonate.

Why Michigan Patients Face Extra Steps

The FDA approved Evenity in April 2019 with a black box warning for increased cardiovascular risk, including myocardial infarction and stroke [2]. Because of this warning and the drug's cost (list price around $1,825 per monthly injection), nearly every Michigan insurer requires prior authorization. That PA process is the single biggest barrier to access.

Step-by-Step: Getting a Romosozumab Prescription in Michigan

The path from first appointment to first injection typically takes 2 to 6 weeks in Michigan, depending on insurance response times. Here is the sequence.

Step 1: See a Qualifying Prescriber

Michigan allows MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) with independent or delegated prescriptive authority to prescribe Evenity. Endocrinologists and rheumatologists write the majority of romosozumab prescriptions. Primary care physicians can also prescribe it, though many prefer to refer out given the cardiovascular monitoring requirements.

Step 2: Complete Baseline Labs and Imaging

Before prescribing, your clinician will order:

• DXA scan (dual-energy X-ray absorptiometry) confirming a T-score of -2.5 or lower at the spine or hip, or evidence of a prior fragility fracture
• Serum calcium and albumin to rule out hypocalcemia (romosozumab can worsen low calcium)
• 25-hydroxyvitamin D level, with supplementation to reach at least 30 ng/mL before starting
• Serum creatinine and eGFR to assess kidney function
• Cardiovascular risk assessment, including blood pressure and lipid panel, given the black box warning for MI and stroke [2]

Patients who have had a myocardial infarction or stroke within the past year are not candidates for romosozumab. The Endocrine Society's 2020 guidelines recommend romosozumab as a first-line option for postmenopausal women at very high fracture risk, defined as a recent fracture, T-score below -3.0, or high FRAX score [3].

Step 3: Submit Prior Authorization

This is where delays happen. Your prescriber's office submits documentation to your insurer showing:

• Confirmed osteoporosis diagnosis with DXA results
• Prior fragility fracture history or FRAX 10-year major osteoporotic fracture probability above 20%
• Documented failure of, intolerance to, or contraindication for at least one first-line agent (typically alendronate or risedronate)
• Cardiovascular risk clearance (no MI or stroke within 12 months)
• Labs confirming adequate calcium and vitamin D levels

Michigan Medicaid covers Evenity with prior authorization for severe osteoporosis. Commercial insurers (Blue Cross Blue Shield of Michigan, Priority Health, HAP, McLaren) each have their own PA criteria, but most follow a similar pattern. Turnaround ranges from 48 hours to 3 weeks.

Telehealth Options for Romosozumab in Michigan

Michigan permits telehealth prescribing for Evenity, and the state's telehealth parity law (Public Act 412 of 2020) requires insurers to cover telehealth visits at the same rate as in-person visits. This means a Michigan-licensed endocrinologist or rheumatologist can evaluate you by video, review your DXA scan and labs, and write the prescription remotely.

What Telehealth Can and Cannot Do

A telehealth visit works well for the initial consultation, lab review, PA coordination, and monthly check-ins. It does not replace the need for a local facility to administer the injection. Romosozumab is given as two subcutaneous injections (two 105 mg prefilled syringes per dose) in a clinical setting. Some patients self-inject at home after training, but the first several doses are typically administered in-office so staff can monitor for injection-site reactions and hypocalcemia symptoms.

Finding a Telehealth Provider

National bone-health telehealth platforms now serve Michigan residents. HealthRX connects patients with licensed clinicians who can prescribe romosozumab and coordinate PA submission. Your prescriber does not need to be physically located in Michigan, but they must hold an active Michigan medical license.

Michigan Pharmacy Access and Specialty Distribution

Evenity is classified as a specialty medication. You will not find it on the shelf at a standard retail pharmacy. Instead, it flows through specialty pharmacy channels.

Specialty Pharmacies

Most Michigan insurers mandate use of a preferred specialty pharmacy. Common options include:

• CVS Specialty (statewide mail-order and local pickup)
• Accredo (Express Scripts' specialty arm)
• OptumRx Specialty (UnitedHealthcare plans)
• Biologics by McKesson
• Amgen's direct distribution through Amgen Assist

After PA approval, the specialty pharmacy ships the prefilled syringes directly to your home or your clinician's office, typically within 3 to 5 business days. The medication must be refrigerated at 2°C to 8°C (36°F to 46°F) and allowed to reach room temperature for 30 minutes before injection.

503A Compounding Pharmacies

Michigan's licensed 503A compounding pharmacies can prepare romosozumab formulations when a patient-specific prescription is provided. This route is less common for romosozumab than for peptides like BPC-157 or sermorelin because the commercially manufactured product (Evenity) is widely available through specialty channels. 503A compounding may be relevant if a patient needs a specific dosage modification or has an allergy to an inactive ingredient in the branded product.

Cost, Copay Assistance, and Michigan-Specific Programs

Twelve months of Evenity at list price runs approximately $21,900 before insurance. Out-of-pocket costs for insured Michigan patients vary widely.

Commercial Insurance

After PA approval, most Michigan commercial plans place Evenity on a specialty tier with a 20% to 30% coinsurance. That translates to $365 to $548 per injection before copay assistance. Amgen's Evenity copay card program can reduce out-of-pocket costs to as low as $0 per month for commercially insured patients, with an annual cap that varies by program year.

Michigan Medicaid

For Medicaid-enrolled patients who meet PA criteria, Evenity is covered with no or minimal copay. The Michigan Department of Health and Human Services requires step therapy documentation showing prior bisphosphonate trial. According to CMS Medicaid drug utilization data, romosozumab prescriptions under state Medicaid programs increased by 34% between 2022 and 2024 [4].

Medicare Part B

Romosozumab administered in a physician's office is covered under Medicare Part B as a physician-administered injectable. The patient pays 20% coinsurance after the Part B deductible ($257 in 2025). For a Medicare beneficiary without supplemental coverage, that means roughly $365 per monthly injection. Amgen's patient assistance program covers eligible Medicare patients who lack supplemental insurance.

Monitoring During the 12-Month Treatment Course

Romosozumab is given as 12 monthly injections. It is not an indefinite treatment. After the 12th dose, patients transition to an anti-resorptive agent (typically denosumab or a bisphosphonate) to maintain the bone density gained.

Monthly and Quarterly Checks

At each injection visit, your clinician should assess:

• Injection-site reactions (reported in 5.2% of patients in the FRAME trial, N=7,180) [5]
• Symptoms of hypocalcemia: muscle cramps, numbness, tingling
• Cardiovascular symptoms: chest pain, shortness of breath, sudden weakness

Serum calcium should be checked at 1 month and again at 3 months. A repeat DXA scan is typically ordered at month 12 to quantify the BMD response before transitioning therapy.

Cardiovascular Vigilance

The ARCH trial found a higher rate of adjudicated major adverse cardiovascular events (MACE) in the romosozumab group compared to the alendronate group during the first 12 months (2.5% vs. 1.9%) [1]. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend against romosozumab in patients with recent cardiovascular events and suggest shared decision-making for patients with cardiovascular risk factors [6]. Michigan clinicians typically obtain a baseline EKG and lipid panel before starting treatment and monitor blood pressure at each visit.

Who Should Consider Romosozumab in Michigan

Not every osteoporosis patient is a candidate. Romosozumab is reserved for the highest-risk group.

Ideal Candidates

• Postmenopausal women with T-scores at or below -2.5 who have already fractured
• Patients who failed or cannot tolerate bisphosphonates (GI intolerance, esophageal disorders, poor absorption)
• Patients with T-scores below -3.0 even without prior fracture
• Patients with a FRAX 10-year major osteoporotic fracture probability above 20% or hip fracture probability above 3%

Who Should Not Use It

• Anyone who has had a heart attack or stroke within the past 12 months
• Patients with uncorrected hypocalcemia
• Patients with known hypersensitivity to romosozumab or any excipient in the formulation

The FDA label states: "Romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. Do not initiate in patients who have had a myocardial infarction or stroke within the preceding year" [2].

Transitioning After 12 Months: What Comes Next

Stopping romosozumab without follow-on therapy leads to rapid bone density loss. This pattern is well-documented. A 2020 analysis published in the Journal of Bone and Mineral Research showed that BMD gains from romosozumab declined within 12 months of discontinuation if no anti-resorptive was started [7].

Common Transition Protocols

Michigan endocrinologists typically choose one of these sequences:

• Romosozumab → denosumab (Prolia, 60 mg subcutaneous every 6 months). This preserves gains most effectively. The ARCH trial used this sequence.
• Romosozumab → alendronate (70 mg oral weekly). A lower-cost option that maintains most of the BMD improvement.
• Romosozumab → zoledronic acid (5 mg IV once yearly). Preferred for patients with poor oral medication adherence.

Your Michigan prescriber should have a documented transition plan before writing the first Evenity prescription. Ask about it at the initial visit.

Timeline: From First Visit to First Injection in Michigan

| Step | Typical Duration | |---|---| | Initial consultation (in-person or telehealth) | Day 1 | | Baseline labs and DXA scan | Days 1 to 7 | | Lab results reviewed, prescription written | Days 7 to 10 | | Prior authorization submitted | Days 10 to 12 | | PA decision received | Days 12 to 28 | | Specialty pharmacy ships medication | Days 28 to 33 | | First injection administered | Days 33 to 40 |

Some patients complete the process in as few as 14 days when labs are already on file and PA is expedited. Others wait 6 weeks or longer if the insurer requests additional documentation or denies the first PA attempt (appeal success rates for romosozumab run approximately 60% to 70% based on industry data from specialty pharmacy networks).